Cover Image
市場調查報告書

全球基因重組蛋白質醫藥品市場

Global Markets for Bioengineered Protein Drugs

出版商 BCC Research 商品編碼 311228
出版日期 內容資訊 英文 146 Pages
訂單完成後即時交付
價格
Back to Top
全球基因重組蛋白質醫藥品市場 Global Markets for Bioengineered Protein Drugs
出版日期: 2016年12月29日 內容資訊: 英文 146 Pages
簡介

全球基因重組蛋白質醫藥品的市場規模,預計從2016年的1725億美元到2021年達到2284億美元,從2016年到2021年的年複合成長率預計為5.8%。

本報告提供全球基因重組蛋白質醫藥品的市場相關調查,基因重組蛋白質醫藥品概要,發展的過程,製造及給藥技術,新的開發趨勢,藥物的各分類、適應症、地區的市場概要及市場收益的變化與預測,產業結構與主要經營者的市場佔有率,專利資訊,主要經營者簡介等詳細內容彙整。

第1章 簡介

第2章 摘要整理

第3章 概要

  • 蛋白質的合成
  • 基因重組蛋白質醫藥品
  • 製造技術
  • 基因重組蛋白質醫藥品的給藥技術
  • 分子分類

第4章 法律規章的方面

  • 單株抗體
  • 細胞激素
  • 疫苗
  • 肽激素
  • 治療用酵素
  • 血液製劑
  • 肽抗體
  • 回收
  • 安全警告

第5章 新的開發

  • 單株抗體
  • 疫苗
  • 細胞激素
  • 肽激素
  • 肽抗體
  • 治療用酵素
  • 血液製劑
  • 肽抗體
  • M&A

第6章 市場分析:各類型

  • 各類型市場
    • 市場概要
    • 市場收益
    • 市場佔有率
    • 肽激素
    • 疫苗
    • 治療用酵素
    • 單株抗體
    • 細胞激素
    • 血液製劑、肽抗體

第7章 產業結構

  • 肽激素
  • 疫苗
  • 治療用酵素
  • 單株抗體
  • 細胞激素
  • 血液因子
  • 肽抗體
  • 產業結構

第8章 市場:各疾病

  • 各疾病市場
    • 市場概要
    • 市場收益
    • 市場佔有率
    • 糖尿病
    • 癌症
    • 血液疾病、皮膚疾病
    • 生長激素障礙、酵素障礙、妊娠障礙
    • 其他

第9章 專利分析

  • 各年度
  • 各類型
  • 各企業
  • 各國
  • 各申請者

第10章 目前情形

  • 基因重組蛋白質醫藥品的影響因素

第11章 企業簡介

  • ABBVIE INC.
  • ACTAVIS INC.
  • ALEXION PHARMACEUTICALS
  • ALLERGAN PLC.
  • AMGEN INC
  • APOTEX INC.
  • BAXALTA INC
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOMARIN PHARMACEUTICAL INC.
  • BIOGEN IDEC
  • BIOTEST PHARMACEUTICALS CORPORATION
  • BRISTOL-MYERS SQUIBB
  • CSL LIMITED
  • ELI LILLY
  • FRESENIUS KABI USA
  • GLAXOSMITHKLINE
  • GRIFOLS USA LLC.
  • HOFFMAN-LA ROCHE
  • HOSPIRA INC.
  • JOHNSON & JOHNSON
  • MEDIMMUNE LLC
  • MERCK & CO, INC
  • MYLAN INC.
  • NOVARTIS AG
  • NOVO NORDISK AG
  • OCTAPHARMA AG
  • PFIZER INC
  • SANOFI INC
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS INC.
  • TAKEDA PHARMACEUTICAL U.S.A., INC
  • UCB COMPANY

第12章 附錄I:簡稱

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO009G

The global market for bioengineered protein drugs is expected to reach $228.4 billion by 2021 from $172.5 billion in 2016, rising at a compound annual growth rate (CAGR) of 5.8% from 2016 through 2021.

Report Includes

  • An overview of the global market for bioengineered protein drugs.
  • Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
  • A look at current technologies underlying the market as well as the effects new technologies will have on the market.
  • An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
  • Profiles major companies involved in the production and modification of protein drugs.

Report Scope

Bioengineered protein drugs are drugs that help treat chronic diseases like diabetes, asthma, cancer, various blood disorders, fertility disorders, immunological disorders and hormonal disorders. This report focuses on the global bioengineered protein drug market and its products, and provides an updated review of its applications in various arenas of biomedical research.

The scope of the study is global. BCC Research analyzes each market and its application, regulatory environment, technologies involved, new products and advancements, market projections and market shares. The technological issues include all the latest trends, pipeline products and developments.

The bioengineered protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, therapeutic enzymes, blood factors, and peptide hormones. These products are all bioengineered and produced by recombinant DNA technology.

The geographical regions covered in the report are North America, Europe, and emerging markets. The emerging market segment covers countries including India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada among others.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead to the bioengineered protein drugs industry. Some of the major players of the market include Eli Lilly and Co., AbbVie Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Novo Nordisk AG, Novartis AG, Merck & Co., Merck KGaA and Amgen Inc., among others.

Analyst Credentials

The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. She was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • BIOSYNTHESIS OF PROTEINS
    • TRANSCRIPTION
    • TRANSLATION
    • POST-TRANSLATIONAL MODIFICATION
  • BIOENGINEERED PROTEIN DRUGS
  • TABLE 1 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
    • HISTORY OF BIOENGINEERED PROTEIN DRUGS
    • TABLE 2 EVOLUTION OF BIOENGINEERED PROTEIN DRUGS
    • ADVANTAGES OF BIOENGINEERED PROTEIN DRUGS
  • MANUFACTURING TECHNOLOGY
    • FRACTIONATION/COHN'S METHOD
    • TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION
    • MICROBIAL/FERMENTATION PROCESS
    • TABLE 4 THERAPETIC DRUGS PRODUCED BY MICROBIAL FERMENTATION
    • GENETIC ENGINEERING
    • GENETICALLY MODIFIED ORGANISMS
    • PHARMING
    • TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS
    • MAMMALIAN CELL CULTURE
    • TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE
  • ADMINISTRATION TECHNOLOGIES OF BIOENGINEERED PROTEIN DRUGS
    • USE OF DRUG DELIVERY SYSTEMS IN CURRENT MEDICAL APPROACHES
    • TRADITIONAL METHODS OF DRUG DELIVERY
      • Oral
      • Topical
      • Trans mucosal
      • Inhalation
      • Parenteral
      • TABLE 7 ROUTES OF DRUG DELIVERY
      • Limitations Encountered by Traditional Drug Delivery
  • MOLECULAR CLASSIFICATION
    • MONOCLONAL ANTIBODIES
    • CYTOKINES
      • Interferons
      • Interleukins
      • Colony Stimulating Factors
    • PEPTIDE HORMONES
      • Follicle Stimulating Hormone and Luteinizing Hormone
      • Growth Hormones
      • Erythropoietin
      • Insulin
    • BLOOD PRODUCTS
      • Alpha 1-Protease Inhibitor
      • Anti-Hemophilic Factor
      • Anti-Thrombin
      • C1-Esterase Inhibitor
      • Coagulation Factors
      • Immunoglobulins
      • Protein C
      • Thrombin
    • PEPTIDE ANTIBIOTICS
    • VACCINES
    • THERAPEUTIC ENZYMES

CHAPTER 4 REGULATORY ASPECTS

  • MONOCLONAL ANTIBODIES
  • TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (FROM 2014-MAY 2016)
  • CYTOKINES
  • TABLE 9 NEW APPROVALS OF CYTOKINES (FROM 2014-2015)*
  • VACCINES
  • TABLE 10 NEW APPROVALS IN VACCINES (FROM 2014-MAY 2016)
  • PEPTIDE HORMONES
  • TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES (FROM 2014-2015)*
  • THERAPUETIC ENZYMES
  • TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES (FROM 2014-2015)*
  • BLOOD PRODUCTS
  • TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS (FROM 2014-MAY 2016)
  • PEPTIDE ANTIBIOTICS
  • TABLE 14 NEW APPROVALS IN PEPTIDE ANTIBIOTICS (FROM 2014-2015)*
  • RECALLS
  • TABLE 15 RECALLS (FROM 2014-2015)*
  • SAFETY ALERTS
  • TABLE 16 SAFETY ALERTS (FROM 2014-2015)*

CHAPTER 5 NEW DEVELOPMENTS

  • MONOCLONAL ANTIBODIES
  • TABLE 17 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES
  • VACCINES
  • TABLE 18 PIPELINE PRODUCTS OF VACCINES
  • CYTOKINES
  • TABLE 19 PIPELINE PRODUCTS OF CYTOKINES
  • PEPTIDE HORMONES
  • TABLE 20 PIPELINE PRODUCTS OF PEPTIDE HORMONES
  • PEPTIDE ANTIBIOTICS
  • TABLE 21 PIEPLINES PRODUCTS OF PEPTIDE ANTIBIOTICS
  • THERAPUETIC ENZYMES
  • TABLE 22 PIPELINE PRODUCTS OF THERAPUETIC ENZYMES
  • BLOOD PRODUCTS
  • TABLE 23 PIPELINE PRODUCTS OF BLOOD PRODUCTS
  • MERGERS AND ACQUISITIONS
  • TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES

CHAPTER 6 MARKET ANALYSIS BY TYPE

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 25 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2021 ($ MILLIONS)
    • FIGURE 1 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2014-2021 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 26 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)
    • FIGURE 2 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)
    • PEPTIDE HORMONES
      • Market Overview
      • Market Revenue
      • TABLE 27 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 3 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, 2014-2021 ($ MILLIONS)
    • VACCINES
      • Market Overview
      • Market Revenue
      • TABLE 28 GLOBAL MARKET FOR VACCINES, BY REGION, THROUGH
      • FIGURE 4 GLOBAL MARKET FOR VACCINES, BY REGION, 2014-2021 ($ MILLIONS)
    • THERAPEUTIC ENZYMES
      • Market Overview
      • Market Revenue
      • TABLE 29 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 5 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2014-2021 ($ MILLIONS)
    • MONOCLONAL ANTIBODIES
      • Market Overview
      • Market Revenue
      • TABLE 30 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 6 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2014-2021 ($ MILLIONS)
    • CYTOKINES
      • Market Overview
      • Market Revenue
      • TABLE 31 GLOBAL MARKET FOR CYTOKINES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 7 GLOBAL MARKET FOR CYTOKINES, BY REGION, 2014-2021 ($ MILLIONS)
    • BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS
      • Market Overview
      • Market Revenue
      • TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 8 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 7 INDUSTRY STRUCTURE

  • PEPTIDE HORMONES
    • MARKET LEADERS
    • TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2015
    • MARKET SHARE
    • TABLE 34 GLOBAL MARKET SHARE OF MANUFACTURERS AND SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)
    • FIGURE 9 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)
  • VACCINES
    • MARKET LEADERS
    • TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2015
    • MARKET SHARE
    • TABLE 36 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)
    • FIGURE 10 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)
  • THERAPEUTIC ENZYMES
    • MARKET LEADERS
    • TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2015
    • MARKET SHARE
    • TABLE 38 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)
    • FIGURE 11 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)
  • MONOCLONAL ANTIBODIES
    • MARKET LEADERS
    • TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2015
    • MARKET SHARE
    • TABLE 40 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)
    • FIGURE 12 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)
  • CYTOKINES
    • MARKET LEADERS
    • TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2015
    • MARKET SHARE
    • TABLE 42 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)
    • FIGURE 13 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)
  • BLOOD FACTORS
    • MARKET LEADERS
    • TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2015
    • MARKET SHARE
    • TABLE 44 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)
    • FIGURE 14 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)
  • PEPTIDE ANTIBIOTICS
    • MARKET LEADERS
    • TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2015
    • MARKET SHARE
    • TABLE 46 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)
    • FIGURE 15 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)

CHAPTER 8 MARKET BY DISEASE

  • MARKET BY DISEASE
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 47 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2021 ($ MILLIONS)
    • FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2014-2021 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 48 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015
    • FIGURE 17 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015 (%)
    • DIABETES
      • Type 1 Diabetes
      • Type 2 Diabetes
      • Gestational Diabetes
      • Market Overview
      • Market Revenue
      • TABLE 49 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, 2014-2021 ($ MILLIONS)
    • CANCER
    • TABLE 50 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN
    • TABLE 51 CATEGORIES OF CANCER
      • Market Overview
      • Market Revenue
      • TABLE 52 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 19 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, 2014-2021 ($ MILLIONS)
    • BLOOD DISORDERS AND SKIN DISEASES
      • Blood Disorders
        • Bleeding Disorders
        • Anemia
        • Leukemia
        • Multiple Myeloma
      • Skin Diseases
        • Skin and Skin structure Infections (SSSI)
          • Complicated Skin and Skin structure Infection (cSSSI)
          • Uncomplicated Skin and Skin structure Infection (uSSSI)
        • Clostridium difficile (C. difficile)
      • Market Overview
      • Market Revenue
      • TABLE 53 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2014-2021 ($ MILLIONS)
    • GROWTH HORMONE DISORDER, ENZYME DISORDER AND FERTILITY DISORDER
      • Market Overview
      • Market Revenue
      • TABLE 54 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 21 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2014-2021 ($ MILLIONS)
    • OTHERS
      • Multiple Sclerosis
      • Hepatitis
      • Crohn's Disease
      • Influenza
      • Pneumonia
      • Cystic Fibrosis
      • Asthma
      • Meningitis
      • Rheumatoid Arthritis
      • Market Overview
      • Market Revenue
      • TABLE 55 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 22 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 9 PATENT ANALYSIS

  • PATENTS BY YEAR
  • TABLE 56 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016
  • FIGURE 23 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016
  • PATENTS BY TYPE
  • TABLE 57 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016
  • FIGURE 24 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016
  • PATENTS BY COMPANY
  • TABLE 58 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COMPANY, 2014-JUNE 2016
  • PATENTS BY COUNTRY
  • TABLE 59 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY,* 2014-JUNE 2016
  • TABLE 60 PATENT SHARES FOR MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY, 2014-JUNE 2016 (NO./%)
  • PATENTS BY ASSIGNEE
  • TABLE 61 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016
  • FIGURE 25 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016

CHAPTER 10 CURRENT SITUATION 137

  • FACTORS AFFECTING BIOENGINEERED PROTEIN DRUGS
    • INCREASING PREVALENCE OF CHRONIC DISEASES
    • GROWING AGING POPULATION
    • LIFESTYLE CHANGES
    • AWARENESS AND EDUCATION
    • ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES
    • PRICE CONTROLS
    • REGULATORY PRESSURES
    • LICENSING AGREEMENTS
    • MERGERS AND ACQUISITIONS
    • ENTRY OF FOLLOW-ON-BIOLOGICS/BIOSIMILARS

CHAPTER 11 COMPANY PROFILES

  • ABBVIE INC.
  • ACTAVIS INC.
  • ALEXION PHARMACEUTICALS
  • ALLERGAN PLC.
  • AMGEN INC
  • APOTEX INC.
  • BAXALTA INC
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOMARIN PHARMACEUTICAL INC.
  • BIOGEN IDEC
  • BIOTEST PHARMACEUTICALS CORPORATION
  • BRISTOL-MYERS SQUIBB
  • CSL LIMITED
  • ELI LILLY
  • FRESENIUS KABI USA
  • GLAXOSMITHKLINE
  • GRIFOLS USA LLC.
  • HOFFMAN-LA ROCHE
  • HOSPIRA INC.
  • JOHNSON & JOHNSON
  • MEDIMMUNE LLC
  • MERCK & CO, INC
  • MYLAN INC.
  • NOVARTIS AG
  • NOVO NORDISK AG
  • OCTAPHARMA AG
  • PFIZER INC
  • SANOFI INC
  • SEATTLE GENETICS INC.
  • SPECTRUM PHARMACEUTICALS INC.
  • TAKEDA PHARMACEUTICAL U.S.A., INC
  • UCB COMPANY

CHAPTER 12 APPENDIX I-ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 1 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
  • TABLE 2 EVOLUTION OF BIOENGINEERED PROTEIN DRUGS
  • TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION
  • TABLE 4 THERAPETIC DRUGS PRODUCED BY MICROBIAL FERMENTATION
  • TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS
  • TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE
  • TABLE 7 ROUTES OF DRUG DELIVERY
  • TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (FROM 2014-MAY 2016)
  • TABLE 9 NEW APPROVALS OF CYTOKINES (FROM 2014-2015)*
  • TABLE 10 NEW APPROVALS IN VACCINES (FROM 2014-MAY 2016)
  • TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES (FROM 2014-2015)*
  • TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES (FROM 2014-2015)*
  • TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS (FROM 2014-MAY 2016)
  • TABLE 14 NEW APPROVALS IN PEPTIDE ANTIBIOTICS (FROM 2014-2015)*
  • TABLE 15 RECALLS (FROM 2014-2015)*
  • TABLE 16 SAFETY ALERTS (FROM 2014-2015)*
  • TABLE 17 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES
  • TABLE 18 PIPELINE PRODUCTS OF VACCINES
  • TABLE 19 PIPELINE PRODUCTS OF CYTOKINES
  • TABLE 20 PIPELINE PRODUCTS OF PEPTIDE HORMONES
  • TABLE 21 PIEPLINES PRODUCTS OF PEPTIDE ANTIBIOTICS
  • TABLE 22 PIPELINE PRODUCTS OF THERAPUETIC ENZYMES
  • TABLE 23 PIPELINE PRODUCTS OF BLOOD PRODUCTS
  • TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES
  • TABLE 25 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)
  • TABLE 27 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR VACCINES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 29 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 30 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 31 GLOBAL MARKET FOR CYTOKINES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2015
  • TABLE 34 GLOBAL MARKET SHARE OF MANUFACTURERS AND SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)
  • TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2015
  • TABLE 36 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)
  • TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2015
  • TABLE 38 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)
  • TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2015
  • TABLE 40 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)
  • TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2015
  • TABLE 42 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)
  • TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2015
  • TABLE 44 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)
  • TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2015
  • TABLE 46 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)
  • TABLE 47 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2021 ($ MILLIONS)
  • TABLE 48 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015
  • TABLE 49 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 50 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN
  • TABLE 51 CATEGORIES OF CANCER
  • TABLE 52 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 53 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 54 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 55 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 56 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016
  • TABLE 57 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016
  • TABLE 58 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COMPANY, 2014-JUNE 2016
  • TABLE 59 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY,* 2014-JUNE 2016
  • TABLE 60 PATENT SHARES FOR MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY, 2014-JUNE 2016 (NO./%)
  • TABLE 61 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 1 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2014-2021 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)
  • FIGURE 3 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR VACCINES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 5 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 6 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 7 GLOBAL MARKET FOR CYTOKINES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 8 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 9 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)
  • FIGURE 10 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)
  • FIGURE 11 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)
  • FIGURE 12 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)
  • FIGURE 13 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)
  • FIGURE 14 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)
  • FIGURE 15 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)
  • FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2014-2021 ($ MILLIONS)
  • FIGURE 17 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015 (%)
  • FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 19 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 21 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 22 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 23 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016
  • FIGURE 24 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016
  • FIGURE 25 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016
Back to Top